NCT00909402 - A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Stomach NeoplasmsEsophageal Neoplasms

Interventions

DRUG

BMS-833923

Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study

DRUG

Cisplatin

Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study

DRUG

Capecitabine

Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study

Trial Locations (6)

Usc/Norris Comprehensive Cancer Center, Los Angeles

Local Institution, Villejuif

City Of Hope National Medical Center, Duarte

The University Of Texas Md Anderson Cancer Center, Houston

Local Institution, Toronto

Local Institution, Amsterdam